Rodman & Renshaw Begins Coverage on Ascentage Pharma Group International (NASDAQ:AAPG)

Investment analysts at Rodman & Renshaw started coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research report issued on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $48.00 price target on the stock. Rodman & Renshaw’s price objective would indicate a potential upside of 69.49% from the company’s current price.

AAPG has been the topic of a number of other research reports. Piper Sandler began coverage on shares of Ascentage Pharma Group International in a report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price target on the stock. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. Truist Financial set a $51.00 price target on Ascentage Pharma Group International in a research report on Monday, November 24th. BTIG Research started coverage on Ascentage Pharma Group International in a research note on Monday, November 10th. They issued a “buy” rating and a $50.00 price objective for the company. Finally, Oppenheimer started coverage on Ascentage Pharma Group International in a research note on Thursday, December 4th. They set an “outperform” rating and a $45.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $48.40.

Ascentage Pharma Group International Price Performance

Shares of Ascentage Pharma Group International stock opened at $28.32 on Tuesday. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. Ascentage Pharma Group International has a 12-month low of $16.50 and a 12-month high of $48.45. The stock’s fifty day moving average is $29.88 and its 200-day moving average is $35.95.

Institutional Trading of Ascentage Pharma Group International

Several large investors have recently made changes to their positions in the stock. UBS Group AG raised its stake in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter. XY Capital Ltd grew its holdings in Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after purchasing an additional 12,530 shares during the last quarter. Tema Etfs LLC bought a new position in shares of Ascentage Pharma Group International in the second quarter valued at approximately $610,000. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International in the second quarter valued at approximately $391,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International in the third quarter worth $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.